CG Oncology (CGON) Insider James Mulay Sells 1,964 Shares

Insider James Mulay completed a transaction involving the stock of CG Oncology, Inc. (NASDAQ:CGON) on June 15, 2026. According to regulatory disclosures filed with the SEC, Mulay exercised options to acquire 1,964 shares at a price of $9.64 per share, representing a total transaction value of $18,925.69.

This transaction follows earlier activity by institutional investors. Back in May, major investment firms like T. Rowe Price and Farallon Capital Management significantly boosted their positions in the clinical-stage biotechnology company, indicating a wave of institutional interest during the second quarter.

CG Oncology Stock Performance

On Tuesday, CG Oncology stock traded at $60.28. The stock has experienced a wide trading range over the past year, hitting a 52-week low of $35.64 and reaching as high as $80.97. It is currently trading below its 50-day moving average of $74.13 and just under its 200-day moving average of $62.63. The company currently has a market capitalization of approximately $6.94 billion.

Recent Earnings

CG Oncology reported revenue of $6.23 million in its latest financial updates. The developer of cancer therapies is not yet profitable, which is common for late-stage clinical biopharmaceutical companies. It posted an earnings per share (EPS) of -$2.69 and has a negative return on equity of 26.4%. Investors looking ahead should note that the company is scheduled to report its next quarterly earnings on November 9, 2026.

Insider Buying and Selling at CG Oncology, Inc.

The transaction by James Mulay on June 15, 2026, involved exercising stock options to buy 1,964 shares at an option price of $9.64. The trade was not executed under a pre-planned Rule 10b5-1 trading schedule. The transaction code indicates this was an option exercise, which allows insiders to purchase shares at a set price determined by previous compensation agreements.

Analysts Set New Price Targets

Wall Street analysts have maintained a highly favorable view of the biotechnology firm. On August 7, 2026, RBC Capital maintained its Outperform rating on the stock, adjusting its price target to $79.00 from $81.00. That same day, Piper Sandler maintained its Overweight rating and bumped its price target up to $85.00 from $82.00. Truist Securities also maintained a Buy rating on August 7, 2026, with a target of $85.00. Overall, thirteen analysts cover the stock, yielding a consensus recommendation of "strong_buy" and an average price target of $91.08.

About CG Oncology

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing immunotherapies for bladder cancer. Its lead product candidate, cretostimogene grenadenorepvec, is undergoing multiple phase 3 clinical trials in the United States to treat patients with high-risk bladder cancer that has not responded to standard therapies.

What's Ahead for CG Oncology, Inc.

Investors will want to monitor the clinical progression of cretostimogene, as well as the company's upcoming earnings report on November 9, 2026, to see how clinical development costs impact its balance sheet. Future regulatory filings will also show whether other company insiders or institutional funds follow suit in adjusting their exposure to CG Oncology.